IMV Inc
TSX:IMV
Intrinsic Value
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IMV.
IMV Inc's market capitalization is 9.2m CAD.
IMV stock price is 1.12 CAD.
IMV.
IMV. Open DCF Valuation
IMV. Open Relative Valuation
IMV.
IMV has positive Net Debt. This means that the company has more debt (29m USD) than cash and short-term investments (21m USD).
IMV's Revenue has grown by an exceptional 37% over the past 12 months.
IMV's long-term liabilties (38m USD) exceed its long-term assets (31m USD).
IMV's ROE (Return on Equity) has significantly decreased in the last 3 years from -196% to -649%, and is approaching profitability.
IMV's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -1 294% to -2 535%, and is approaching profitability.
IMV has negative Operating Income for the last twelve months.
IMV has negative Net Income for the last twelve months.
IMV's ROE (Return on Equity) for the past 12 months is negative and is equal to -649%.
IMV's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 535%.
IMV's short-term assets (28m USD) exceed its short-term liabilties (9m USD).
IMV has negative Free Cash Flow for the last twelve months.
IMV has negative three-year average ROE (Return on Equity): -276%. The company is not efficient at transforming stockholders' equity into net income.
IMV has negative three-year average ROIC (Return on Invested Capital): -1 508%. The company is not efficient at using invested capital to generate operating income.
IMV's D/E (Debt to Equity) is very low and is equal to -4.32.
IMV's Altman Z-Score is very low and is equal to -13.21.
Fundamental Analysis
IMV Inc
Balance Sheet Decomposition
IMV Inc
| Current Assets | 27.6m |
| Cash & Short-Term Investments | 21.2m |
| Receivables | 1.9m |
| Other Current Assets | 4.4m |
| Non-Current Assets | 3.8m |
| PP&E | 3.8m |
| Current Liabilities | 9.4m |
| Accounts Payable | 9m |
| Other Current Liabilities | 383k |
| Non-Current Liabilities | 28.5m |
| Long-Term Debt | 28.5m |
Earnings Waterfall
IMV Inc
|
Revenue
|
354k
USD
|
|
Operating Expenses
|
-50.9m
USD
|
|
Operating Income
|
-50.5m
USD
|
|
Other Expenses
|
2m
USD
|
|
Net Income
|
-48.5m
USD
|
Free Cash Flow Analysis
IMV Inc
IMV Profitability Score
Profitability Due Diligence
IMV Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
IMV Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
IMV Solvency Score
Solvency Due Diligence
IMV Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
IMV Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMV Price Targets Summary
IMV Inc
Shareholder Return
IMV Price
IMV Inc
| Average Annual Return | -30.6% |
| Standard Deviation of Annual Returns | 26.8% |
| Max Drawdown | -99% |
| Market Capitalization | 9.2m CAD |
| Shares Outstanding | 8 237 000 |
| Percentage of Shares Shorted | 0.14% |
Company Profile
IMV Inc
Country
Industry
Market Cap
Dividend Yield
Description
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
You don't have any saved screeners yet
